Top

Infection

Published in:

01-10-2016 | Review

Occult HBV infection in the oncohematological setting

Authors: C. Sagnelli, M. Macera, M. Pisaturo, R. Zampino, M. Coppola, E. Sagnelli

Published in: Infection | Issue 5/2016

Abstract

Introduction

Occult hepatitis B infection (OBI), a virological condition characterized by a low release of Hepatitis B Virus (HBV) from liver cells and low HBV-DNA levels in serum and/or liver tissue of HBsAg-negative subjects, may reactivate in oncohematological patients undergoing immunosuppression by aggressive chemotherapy or hematopoietic stem cell transplantation. The entity of OBI reactivation varies from an increase in HBV replication without liver damage to an active HBV replication followed by liver cell necrosis, frequently severe and in some cases life threatening. Because of a possible severe outcome associated with OBI reactivation (hepatic failure or death due to the discontinuation of chemotherapy), prophylaxis with anti-HBV nucleot(s)ide analogues is recommended in relation to the foreseeable degree of immunosuppression.

Materials and methods

This review article focuses on the clinical impact of OBI in the oncohematological setting and is addressed to all health care workers having in care oncohematological patients or involved in the treatment of HBV infection and OBI prophylaxis.

Conclusion

International guidelines have indicated lamivudine prophylaxis in hematopoietic stem cell transplantation and when high-dose corticosteroids or anti-CD20 or anti-CD52 monoclonal antibodies are used. Entecavir or tenofovir should replace lamivudine for patients with advanced liver diseases for whom reactivation of OBI may be life threatening. When anti-CD20 or anti-CD52 sparing schedules or other non-aggressive chemotherapies are used, monitoring may be indicated, but very early treatment with highly effective antiviral drugs (entecavir or tenofovir) should be administered once a reactivation of OBI has occurred.

Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479–86. doi:10.1016/S14733099(02)00345-6.CrossRefPubMed

Izmirli S, Celik DG, Yuksel P, Saribas S, Aslan M, Ergin S, et al. The detection of occult HBV infection in patients with HBsAg negative pattern by real-time PCR method. Transfus Apher Sci. 2012;47:283–7. doi:10.1016/j.transci.2012.07.009.CrossRefPubMed

Coppola N, Loquercio G, Tonziello G, Azzaro R, Pisaturo M, Di Costanzo G, et al. HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol. 2013;58:315–7. doi:10.1016/j.jcv.2013.06.020.CrossRefPubMed

Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652–7. doi:10.1016/j.jhep.2008.07.014.CrossRefPubMed

Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”. Hepatology. 2001;34:194–203.CrossRefPubMed

Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Günther S, et al. Serological pattern “anti-HBc alone”: report on a workshop. J Med Virol. 2000;62:450–5.CrossRefPubMed

Jilg W, Hottenträger B, Weinberger K, Schlottmann K, Frick E, Holstege A, et al. Prevalence of markers of hepatitis B in the adult German population. J Med Virol. 2001;63:96–102.CrossRefPubMed

Weber B, Melchior W, Gehrke R, Doerr HW, Berger A, Rabenau H. Hepatitis B virus markers in anti-HBc only positive individuals. J Med Virol. 2001;64:312–9.CrossRefPubMed

Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat. 2002;9:243–57.CrossRefPubMed

10.

Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010;48:23–9. doi:10.1515/CCLM.2010.002.CrossRefPubMed

11.

Schmeltzer P, Sherman KE. Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci. 2010;55:3328–35. doi:10.1007/s10620-010-1413-0.CrossRefPubMedPubMedCentral

12.

Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142–142. doi:10.1128/CMR.00018-11.CrossRefPubMedPubMedCentral

13.

Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22–6. doi:10.1056/NEJM199907013410104.CrossRefPubMed

14.

Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol. 2013;35:39–52. doi:10.1007/s00281-012-0327-7.CrossRefPubMed

15.

Marusawa H, Osaki Y, Kimura T, Ito K, Yamashita Y, Eguchi T, et al. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut. 1999;45:284–8.CrossRefPubMedPubMedCentral

16.

Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol. 1999;58:201–7.CrossRefPubMed

17.

Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253–60. doi:10.1097/01.aids.0000232232.41877.2a.CrossRefPubMed

18.

Neau D, Winnock M, Jouvencel AC, Faure M, Castéra L, Legrand E, et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: aquitaine cohort, 2002-2003. Clin Infect Dis. 2005;40:750–3. doi:10.1128/CMR.00018-11.CrossRefPubMed

19.

Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology. 1993;17:20–9.CrossRefPubMed

20.

Kubo S, Kim YJ, Ohba K, Shuto T, Yamamoto T, Tanaka H, et al. Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis. Dig Dis Sci. 2001;46:2408–14.CrossRefPubMed

21.

Sheu JC, Huang GT, Shih LN, Lee WC, Chou HC, Wang JT, et al. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology. 1992;103:1322–7.CrossRefPubMed

22.

Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126:102–10.CrossRefPubMed

23.

Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 2006;106:1326–30.CrossRefPubMed

24.

Coppola N, Pisapia R, Tonziello G, Martini S, Imparato M, Piai G, et al. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection. Antivir Ther. 2008;13:307–18.PubMed

25.

Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol. 2008;80:15471553. doi:10.1002/jmv.21239.

26.

Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90:1219–23. doi:10.1007/s00277-011-1241-0.CrossRefPubMed

27.

Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood. 2009;113:3147–53. doi:10.1182/blood2008-10-163493.CrossRefPubMed

28.

Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712. doi:10.1111/j.1365-2141.2006.06465.x.CrossRefPubMed

29.

Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23. doi:10.1007/s12185-009-0359-5.CrossRefPubMed

30.

Montineri A, Nigro L, La Rosa R, Iacobello C, Larocca L, Cappello E, et al. Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: a clinical survey of 5 cases in Catania, Italy. J Clin Virol. 2011;52:284–7. doi:10.1016/j.jcv.2011.08.007.CrossRefPubMed

31.

Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397–408. doi:10.1016/j.dld.2006.12.017.CrossRefPubMed

32.

Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol. 2011;83:1909–16. doi:10.1002/jmv.22199.CrossRefPubMed

33.

Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.CrossRefPubMed

34.

Ustün C, Koç H, Karayalcin S, Akyol G, Gürman G, Ilhan O, et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;20:289–96. doi:10.1038/sj.bmt.1700885.CrossRefPubMed

35.

Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99:2324–30. doi:10.1182/blood.V99.7.2324.CrossRefPubMed

36.

Ma SY, Lau GK, Cheng VC, Liang R. Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma. 2003;44:1281–5. doi:10.1080/1042819031000083343.CrossRefPubMed

37.

Knöll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:925–9. doi:10.1038/sj.bmt.1704457.CrossRefPubMed

38.

Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol. 2005;42:813–9. doi:10.1016/j.jhep.2005.01.018.CrossRefPubMed

39.

Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation. 2005;79:616–9. doi:10.1097/01.TP.0000151661.52601.FB.CrossRefPubMed

40.

Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximab related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48:1307–12. doi:10.1080/10428190701411441.CrossRefPubMed

41.

Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L, et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection. 2010;38:58–61. doi:10.1007/s15010-009-9019-1.CrossRefPubMed

42.

Coppola N, Gentile I, Pasquale G, Buonomo AR, Capoluongo N, D’Armiento M, et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol. 2014;13:20–6.

43.

Jang JY, Park EJ. Occult hepatitis B virus infection in chronic hepatitis C. Korean J Gastroenterol. 2013;62:154159.CrossRef

44.

Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol. 2011;17:3881–7. doi:10.3748/wjg.v17.i34.3881.CrossRefPubMedPubMedCentral

45.

Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat. 2010;17:807–15.CrossRefPubMed

46.

Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol. 2014;6:384–93. doi:10.4254/wjh.v6.i6.384.CrossRefPubMedPubMedCentral

47.

Sagnelli E, Sagnelli C, Pisaturo M, Coppola N. Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection. World J Gastroenterol. 2014;20:6707–15. doi:10.3748/wjg.v20.i22.6707.CrossRefPubMedPubMedCentral

48.

Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME, et al. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat. 2007;14:213–20.CrossRefPubMed

49.

Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology. 1998;27:1736–42.CrossRefPubMed

50.

Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89:255–62. doi:10.1007/s00277-009-0806-7.CrossRefPubMed

51.

Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605611. doi:10.1200/JCO.2008.18.0182.CrossRef

52.

Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine. 2002;81:213–27.CrossRefPubMed

53.

Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology. 2008;134:1470–81. doi:10.1053/j.gastro.2008.02.017.CrossRefPubMed

54.

Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011;17:1927–38. doi:10.3748/wjg.v17.i15.1927.CrossRefPubMedPubMedCentral

55.

Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat. 2010;17:1–15. doi:10.1111/j.1365-2893.2009.01245.x.CrossRefPubMed

56.

Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepato-cellular carcinoma. Hepatology. 2007;45:277–85.CrossRefPubMed

57.

Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, Wu X, Peng J, Xu B, Lin Y, Cao Y, Li H, Lin S, Liu Q, Lin T. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312:2521–30. doi:10.1001/jama.2014.15704.CrossRefPubMed

58.

Squadrito G, Spinella R, Raimondo G. The clinical significance of occult HBV infection. Ann Gastroenterol. 2014;27:15–9.PubMedPubMedCentral

59.

European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42. doi:10.1016/j.jhep.2009.02.017.CrossRef

60.

Barclay S, Pol S, Mutimer D, Benhamou Y, Mills PR, Hayes PC, et al. The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. J Clin Virol. 2008;41:243–54. doi:10.1016/j.jcv.2007.11.017.CrossRefPubMed

61.

Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.CrossRefPubMed

62.

Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B cell lymphoma. Cancer. 2010;116:4769–76. doi:10.1002/cncr.25253.CrossRefPubMed

63.

Cheung WI, Lin SY, Leung VKS, Fung KSC, Lam YK, Lo FH, et al. Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy. Hong Kong Med J. 2011;17:376–80.PubMed

64.

Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Cecchini E, et al. Reactivation of hepatitis B virus replication due to cytotoxic therapy: a five-year prospective study. Tumor. 2012;98:220–4. doi:10.1700/1088.11933.

65.

Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, et al. Management of the HBV reactivation in isolated HBcAb positive patients affected with non Hodgkin lymphoma. BMC Gastroenterol. 2014;14:31–40. doi:10.1186/1471-230X-14-31.CrossRefPubMedPubMedCentral

66.

Elkady GA, Aboulfotuh S, Ali EM, Sayed D, Abdel-Aziz NM, Ali AM, et al. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt. World J Gastroenterol. 2013;19:6214–20. doi:10.3748/wjg.v19.i37.6214.CrossRefPubMedPubMedCentral

67.

Zachou K, Sarantopoulos A, Gatselis NK, Vassiliadis T, Gabeta S, Stefos A, et al. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: a hidden threat. World J Hepatol. 2013;5:387–92. doi:10.4254/wjh.v5.i7.387.CrossRefPubMedPubMedCentral

68.

Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092–100.CrossRefPubMed

69.

Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39.CrossRefPubMed

70.

Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta analysis. J ClinVirol. 2013;57:209–14. doi:10.1016/j.jcv.2013.03.010.

71.

Baginski I, Chemin I, Hantz O, Pichoud C, Jullien AM, Chevre JC, et al. Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of post transfusion hepatitis. Transfusion. 1992;32:215–20. doi:10.1046/j.1537-2995.1992.32392213803.x.CrossRefPubMed

72.

Liu WP, Zheng W, Song YQ, Ping LY, Wang GQ, Zhu J. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin’s lymphoma. World J Gastroenterol. 2014;20:5165–70. doi:10.3748/wjg.v20.i17.5165.CrossRefPubMedPubMedCentral

73.

Tonziello G, Pisaturo M, Sica A, Ferrara MG, Sagnelli C, Pasquale G, et al. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection. 2013;41(1):225–9. doi:10.1007/s15010-012-0305-y.CrossRefPubMed

74.

Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab based regimens treatment? Am J Hematol. 2008;83:673–5. doi:10.1002/ajh.21214.CrossRefPubMed

75.

Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009;36:1188–94. doi:10.3899/jrheum.081246.CrossRefPubMed

76.

Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46:556–64.CrossRefPubMed

77.

Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, Kim TY, Sohn JH, Lee HS. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol. 2010;37:346–50. doi:10.3899/jrheum.090436.CrossRefPubMed

78.

Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013;31:118–21.PubMed

79.

Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21:1366–71. doi:10.1111/j.1440-1746.2006.04559.x.CrossRefPubMed

80.

Biondo MI, Germano V, Pietrosanti M, Canzoni M, Marignani M, Stroffolini T, Salemi S, D’Amelio R. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies. Eur J Intern Med. 2014;25:482–4. doi:10.1016/j.ejim.2013.11.014.CrossRefPubMed

81.

Morisco F, Guarino M, La Bella S, Di Costanzo L, Caporaso N, Ayala F, Balato N. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterol. 2014;14:214. doi:10.1186/s12876-014-0214-x.CrossRefPubMedPubMedCentral

82.

Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection—EASL Special Conference. J Hepatol. 2015;63:1238–53. doi:10.1016/j.jhep.2015.06.026.CrossRefPubMed

83.

Coppola N, Sagnelli C, Pisaturo M, Minichini C, Messina V, Alessio L, et al. Clinical and virological characteristics associated with severe acute hepatitis B. Clin Microbiol Infect. 2014;20:O991–7. doi:10.1111/1469-0691.12720.CrossRefPubMed

84.

Sagnelli C, Ciccozzi M, Pisaturo M, Zehender G, Lo Presti A, Alessio L, et al. Molecular epidemiology of hepatitis B virus genotypes circulating in acute hepatitis B patients in the Campania region. J Med Virol. 2014;86:1683–93. doi:10.1002/jmv.24005.CrossRefPubMed

85.

Coppola N, Masiello A, Tonziello G, Pisapia R, Pisaturo M, Sagnelli C, et al. Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. J Viral Hepat. 2010;17:493–500. doi:10.1111/j.1365-2893.2009.01201.x.PubMed

Title: Occult HBV infection in the oncohematological setting
Authors: C. Sagnelli
M. Macera
M. Pisaturo
R. Zampino
M. Coppola
E. Sagnelli
Publication date: 01-10-2016
Publisher: Springer Berlin Heidelberg
Published in: Infection / Issue 5/2016
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-016-0891-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Occult HBV infection in the oncohematological setting

Abstract

Introduction

Materials and methods

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Materials and methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2016

A case of pharyngeal diphtheria in Germany, June 2015

Septic arthritis of the knee due to Raoultella ornithinolytica

Early ventriculoperitoneal shunt infection

Antibiotic stewardship in a tertiary care hospital of a developing country: establishment of a system and its application in a unit—GASP Initiative

Medium-grade tubular proteinuria is common in HIV-positive patients and specifically associated with exposure to tenofovir disoproxil Fumarate

Cranial imaging findings in neurobrucellosis: results of Istanbul-3 study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page